Quick guide to competing interests for EMA experts
Quick guide to competing interests for EMA experts
Quick guide to competing interests for EMA experts
Questions and answers on Implementing Regulation (EU) 2025/1466: Amendment of Regulation (EU) No 520/2012 and Conclusion of the Signal Detection in EudraVigilance Pilot by marketing authorisation holders
Article 57 product data
Workshop on a tailored clinical approach in biosimilar development, Online, European Medicines Agency, Amsterdam, the Netherlands, from 22 September 2025, 09:00 (CEST) to 22 September 2025, 16:00 (CEST)
Human medicines European public assessment report (EPAR): Viagra, sildenafil, Date of authorisation: 13/09/1998, Revision: 51, Status: Authorised
Human medicines European public assessment report (EPAR): Revatio, sildenafil, Date of authorisation: 28/10/2005, Revision: 54, Status: Authorised
UPD registration guide for UI and API users
Worksharing of variations (veterinary medicines)
Human medicines European public assessment report (EPAR): Bomyntra, denosumab, Date of authorisation: 17/07/2025, Status: Authorised
First European Medicines Agency (EMA) and Association of Clinical Research Organizations (ACRO) bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 2 September 2025